{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:38:33Z","timestamp":1792093113461,"version":"4.4.0"},"reference-count":43,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005929","name":"Danish Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005929","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008733","name":"H\u00f8rslev-Fonden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008733","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Laboratoires THEA"},{"name":"Fight for Sight Denmark"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2021,11,30]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the short-term impact on human conjunctival goblet cell (GC) survival and mucin release of acute exposure to benzalkonium chloride (BAK) preserved and preservative-free (PF) 0.005% (w\/v) latanoprost (LT) eye drops, and to compare the eye drops\u2019 physicochemical properties.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>Primary GC cultures were established from human conjunctival donor tissue. The impact of eye drops on GC survival was assessed using a lactate dehydrogenase assay. Mucin release was evaluated through mucin-specific immunostaining. pH value, osmolality, drop mass and surface tension for all LT eye drops were measured.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After application with PF-LT for 30\u2009min (min), the GC survival was maintained compared with control (p=0.9941), while all BAK-LT eye drops reduced survival with approximately 30% (p&lt;0.02). Following application with PF-LT for 30\u2009min, mucin was found around the GC nucleus, as seen in the vehicle control, indicating no secretion. In contrast, BAK-LT caused diffuse staining of mucin, similar to the secretagogue histamine, indicating stimulation of secretion. The pH value of the BAK-LT and PF-LT eye drops were 6.0\u20136.9 and 6.8, respectively. The osmolality was 258\u2013288 mOsm\/kg for the BAK-LT eye drops and 276 for PF-LT eye drops. The mean drop mass was 26\u201331\u2009mg for the BAK-LT eye drops and 30\u2009mg for PF-LT. The surface tension was lower for all BAK-LT eye drops (31.1\u201332.1 mN\/m) compared with PF-LT (42 mN\/m).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PF-LT compared with various branded and generic LT preparations containing BAK are less cytotoxic when applied to cultured GCs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2021-000892","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T13:32:24Z","timestamp":1640007144000},"page":"e000892","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of benzalkonium chloride-preserved and preservative-free latanoprost eye drops on cultured human conjunctival goblet cells upon acute exposure and differences in physicochemical properties of the eye drops"],"prefix":"10.1136","volume":"6","author":[{"given":"Olivia","family":"M\u00fcllertz","sequence":"first","affiliation":[{"name":"Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7556-4658","authenticated-orcid":false,"given":"Anne","family":"Hedengran","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaynab Ahmad","family":"Mouhammad","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-7226","authenticated-orcid":false,"given":"Josefine","family":"Freiberg","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rich\u00e1rd","family":"Nagymih\u00e1ly","sequence":"additional","affiliation":[{"name":"Center for Eye Research, Department of Ophthalmology, Oslo University Hospital and Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Weng","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bair","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor P","family":"Utheim","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo Universitetssykehus, Oslo, Norway"},{"name":"Department of Ophthalmology, S\u00f8rlandet Hospital Arendal, Arendal, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-6932","authenticated-orcid":false,"given":"Darlene A","family":"Dartt","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Heegaard","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Petrovski","sequence":"additional","affiliation":[{"name":"Center for Eye Research, Department of Ophthalmology, Oslo University Hospital and Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-0734","authenticated-orcid":false,"given":"Miriam","family":"Kolko","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"2025090109282388000_6.1.e000892.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"2025090109282388000_6.1.e000892.2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132048"},{"key":"2025090109282388000_6.1.e000892.3","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12203"},{"key":"2025090109282388000_6.1.e000892.4","unstructured":"European Glaucoma Society . Terminology and guidelines for glaucoma. 5 edn, 2020."},{"key":"2025090109282388000_6.1.e000892.5","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200004000-00008"},{"key":"2025090109282388000_6.1.e000892.6","first-page":"1967","article-title":"Latanoprost in the treatment of glaucoma","volume":"8","author":"Alm","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"2025090109282388000_6.1.e000892.7","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.19082\/2954","article-title":"Adherence to treatment in patients with open-angle glaucoma and its related factors","volume":"8","author":"Movahedinejad","year":"2016","journal-title":"Electron Physician"},{"key":"2025090109282388000_6.1.e000892.8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/OPTH.S150816","article-title":"Glaucoma therapy: preservative-free for all?","volume":"12","author":"Thygesen","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"2025090109282388000_6.1.e000892.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2018.11.007","article-title":"Reconsidering the central role of mucins in dry eye and ocular surface diseases","volume":"71","author":"Baudouin","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"2025090109282388000_6.1.e000892.10","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/03007995.2016.1202818","article-title":"Preservative-Free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension","volume":"32","author":"Aptel","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"2025090109282388000_6.1.e000892.11","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2147\/OPTH.S176605","article-title":"Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life free study","volume":"12","author":"Economou","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"2025090109282388000_6.1.e000892.12","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302121"},{"key":"2025090109282388000_6.1.e000892.13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2147\/OPTH.S295821","article-title":"Real world study on patient satisfaction and tolerability after switching to preservative-free latanoprost","volume":"15","author":"Erb","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"2025090109282388000_6.1.e000892.14","doi-asserted-by":"crossref","first-page":"bjophthalmol-2019-315623","DOI":"10.1136\/bjophthalmol-2019-315623","article-title":"Efficacy and safety evaluation of benzalkonium chloride preserved eye drops compared with alternatively preserved and preservative-free eye drops in the treatment of glaucoma: a systematic review and meta-analysis","volume":"104","author":"Hedengran","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"2025090109282388000_6.1.e000892.15","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1067"},{"key":"2025090109282388000_6.1.e000892.16","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12131"},{"key":"2025090109282388000_6.1.e000892.17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jtos.2017.03.004","article-title":"Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost","volume":"15","author":"Martinez-de-la-Casa","year":"2017","journal-title":"Ocul Surf"},{"key":"2025090109282388000_6.1.e000892.18","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1111\/j.1755-3768.2011.02338.x","article-title":"Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial","volume":"90","author":"Stevens","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"2025090109282388000_6.1.e000892.19","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6248185"},{"key":"2025090109282388000_6.1.e000892.20","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-010-0070-1"},{"key":"2025090109282388000_6.1.e000892.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2012.02565.x"},{"key":"2025090109282388000_6.1.e000892.22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.22336\/rjo.2019.38","article-title":"Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost","volume":"63","author":"Kumar","year":"2019","journal-title":"Rom J Ophthalmol"},{"key":"2025090109282388000_6.1.e000892.23","unstructured":"EMA . Generic and hybrid medicines, 2019. Available: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/generic-hybrid-medicines"},{"key":"2025090109282388000_6.1.e000892.24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10792-016-0280-x","article-title":"Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations","volume":"37","author":"Angmo","year":"2017","journal-title":"Int Ophthalmol"},{"key":"2025090109282388000_6.1.e000892.25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/aos.13355","article-title":"The physical properties of generic latanoprost ophthalmic solutions are not identical","volume":"95","author":"Kolko","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"2025090109282388000_6.1.e000892.26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2015.11.021","article-title":"Variation in number of doses, bottle volume, and calculated yearly cost of generic and branded latanoprost for glaucoma","volume":"163","author":"Queen","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"2025090109282388000_6.1.e000892.27","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-0550"},{"key":"2025090109282388000_6.1.e000892.28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000517845","article-title":"Benzalkonium Chloride-Preserved anti-glaucomatous eye drops and their effect on human conjunctival goblet cells in vitro","volume":"6","author":"Hedengran","year":"2021","journal-title":"Biomed Hub"},{"key":"2025090109282388000_6.1.e000892.29","first-page":"40","article-title":"In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis)","volume":"110","author":"Baudouin","year":"2012","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2025090109282388000_6.1.e000892.30","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1167\/iovs.16-20903","article-title":"The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells","volume":"58","author":"Datta","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109282388000_6.1.e000892.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.06.003"},{"key":"2025090109282388000_6.1.e000892.32","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8748"},{"key":"2025090109282388000_6.1.e000892.33","first-page":"1","article-title":"A new trend: ocular drug delivery system","volume":"2","author":"Jitendra","year":"2011","journal-title":"PharmaSci Monit"},{"key":"2025090109282388000_6.1.e000892.34","first-page":"127-39","article-title":"[Original preparations versus generics--latanoprost: how similar is different?]","volume":"112","author":"Leitritz","year":"2015","journal-title":"Ophthalmologe"},{"key":"2025090109282388000_6.1.e000892.35","unstructured":"government U . Latanoprost (Xalatan): increased reporting of eye irritation since reformulation. Available: https:\/\/www.gov.uk\/drug-safety-update\/latanoprost-xalatan-increased-reporting-of-eye-irritation-since-reformulation#fnref:1 [Accessed 3 May 2020]."},{"key":"2025090109282388000_6.1.e000892.36","unstructured":"fda.gov . XALATAN\u00ae (latanoprost ophthalmic solution) 0.005%. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020597s051lbl.pdf [Accessed 4 May 2020]."},{"key":"2025090109282388000_6.1.e000892.37","unstructured":"medicines.org.uk . Xalatan 50 micrograms\/ml eye drops solution - patient leaflet, 2020. Available: https:\/\/www.medicines.org.uk\/emc\/product\/1616\/pil [Accessed 4 May 2020]."},{"key":"2025090109282388000_6.1.e000892.38","unstructured":"medicines.org.uk . Xalatan 50 micrograms\/ml eye drops solution - SmPC, 2020. Available: https:\/\/www.medicines.org.uk\/emc\/product\/1616\/smpc [Accessed 4 May 2020]."},{"key":"2025090109282388000_6.1.e000892.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1444-0938.2011.00634.x"},{"key":"2025090109282388000_6.1.e000892.40","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70028-9"},{"key":"2025090109282388000_6.1.e000892.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70081-2"},{"key":"2025090109282388000_6.1.e000892.42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/02713688909000031","article-title":"Tear film stability and tear surface tension","volume":"8","author":"Tiffany","year":"1989","journal-title":"Curr Eye Res"},{"key":"2025090109282388000_6.1.e000892.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.08.010"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2021-000892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:28:38Z","timestamp":1756744118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2021-000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,20]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bmjophth-2021-000892"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2021-000892","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}